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Abstract Increasing age is an important prognostic var-
iable in glioblastoma (GBM). We have defined the pro-
teomic response in GBM samples from 7 young patients
(mean age 36 years) compared to peritumoural-control
samples from 10 young patients (mean age 32 years).
2-Dimensional-gel-electrophoresis, image analysis, and
protein identification (LC/MS) were performed. 68 proteins
were significantly altered in young GBM samples with 29
proteins upregulated and 39 proteins downregulated. Over
50 proteins are described as altered in GBM for the first
time. In a parallel analysis in old GBM (mean age
67 years), an excellent correlation could be demonstrated
between the proteomic profile in young GBM and that in
old GBM patients (r2 = 0.95) with only 5 proteins altered
significantly (p \ 0.01). The proteomic response in young
GBM patients highlighted alterations in protein–protein
interactions in the immunoproteosome, NFkB signalling,
and mitochondrial function and the same systems partici-
pated in the responses in old GBM patients.
Keywords Clinical proteomics  Glioblastoma  Patient
age
Introduction
Patients diagnosed with Glioblastoma (GBM, WHO-IV)
have extremely poor median survival times, despite mod-
ern microsurgery, chemoradiotherapy, reoperation and
experimental therapies [1–4]. To improve GBM treatment
and patient median survival times, fresh insight into the
molecular pathogenesis of GBM is essential. Proteomics
can define molecular pathways and cellular functions
altered in GBM [5]. Genomic studies, although important,
are limited by the fact that normal, upregulated or mutated
genes may not be transcribed for a number of epigenetic
reasons [6]. Multiple discrepancies between mRNA and
proteomic expression profiles in differential analyses of
gliomas highlight the importance of studying protein
expression [7].
Age is a powerful individual prognostic indicator [8–
10]. Long term survivors of GBM are invariably younger
patients [8–10], and in one randomised clinical trial,
median survival for GBM cohorts aged \45 years was
48 weeks compared to 19 weeks for those [65 years; and
at 18 months 23 % of the younger cohort was alive com-
pared to 3 % of the older cohort [8]. Numerous randomised
controlled trials and hospital series have excluded differ-
ences in access to health care as the cause for this differ-
ential outcome [1, 9–12].
The biological basis of this powerful age-related effect
is not understood. The histological features of GBM,
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cellular proliferative indices, epidermal growth factor
receptor amplification and p53 expression are very similar
irrespective of age [9]. Although younger patients are more
likely to have secondary GBM than the elderly [3, 9, 13],
there is no difference in outcomes between primary and
secondary GBM once the diagnosis is made and patients
have been aged matched with controls [13]. Although
genetic differences associated with short survival (6q loss,
10q loss, 19q gain, sodium ion channel mutations) and
longer survival (TP53 mutations and the combination of
LOH1p and LOH19q, MGMT status, mutation of IDH1)
have been identified, these differences have not, with the
exception of IDH1 mutations where the mutation occurred
in younger patients, been analysed with respect to patient
age [14–20].
Analyses of GBM samples from older patients has
begun to provide a coherent view of the proteomic
response in GBM but interpretation is complicated by
differences in experimental design and proteomic tech-
nology [5]. In this study we provide the first systematic
proteomic analysis in young GBM (versus age-matched
peritumoural-control brain) to gain insight into the basis of
the importance of age on prognosis. For the purpose of
comparison, we performed a parallel, contemporaneous
study (using the same experimental design and technology)
in old GBM.
Materials and methods
Clinical material
Glioblastoma and peritumoural-control brain samples were
obtained from young (\45 years) and old patients
([60 years) undergoing resective brain tumour surgery
(Ethical approval: LREC/2004/4/16). The sampling pro-
cedure and clinical details of experimental samples are
described in Supplementary Tables 1 and 2 and Supple-
mentary methods.
The experimental group sizes used for the primary pro-
teomic analysis were young GBM (n = 7) and young peri-
tumoural-control (n = 12) (based on a priori power
calculations to detect significant changes of C35 % with
power C0.8). Tissue was collected for two comparison
groups: old GBM (n = 13) and old peritumoural-control
(n = 10). The median co-efficients of variation were similar
in each experimental group: young GBM 33.55 %, young
peritumoural-control 27.38 %, old GBM 33.99 % and old
peritumoural-control 26.39 % (Supplementary Fig. 1).
Total protein extracts were separated by isoelectric
point and molecular mass using 2DGE (see Supplemen-
tary-methods). 2D-gel images were captured using a
FluorChem Image Analyser and aligned in a single study
using at least four manual alignment vectors followed by
automatic placement of further alignment vectors by the
software (*200–400 vectors per gel). The mean protein
levels of each protein were analysed using Student’s t test
(p B 0.003, equivalent to p B 0.01 with Bonferroni cor-
rection factor 3 for each comparison). Significant data are
presented in Table 1 (uncorrected for multiple compari-
sons) and all data are presented in Supplementary
Table 3. Protein spots differentially expressed in young
GBM versus young peritumoural-control were manually
excised and proteins identified using LC–MS [21]. LC–
MS runs of each sample were combined using Maxquant,
assuming a false positive rate of 0.01 [22]. An identical
approach was applied in parallel comparing old GBM
versus old peritumoural-control, and young GBM versus
old GBM.
Immunoblot analysis was performed on a subset of the
tissue samples used for proteomics. Proteins (10 lg) were
separated by SDS-PAGE and transferred to nitrocellulose
membrane. Primary antibodies were detected using fluo-
rescently-labelled secondary antibodies and were visual-
ized using an Odyssey Imager.
To assess functional protein–protein interactions
between the proteins altered in young GBM (p B 0.01),
altered protein identifiers were uploaded to Ingenuity
Pathway Analysis (IPA; http://www.ingenuity.com). Net-
works were algorithmically generated based on direct
relationships (physical interactions and/or associations)
between eligible proteins. Networks are scored and ranked
according to the inclusion of as many proteins inputted as
possible. Network scores are putatively a measure of
probability [23]. For comparison purposes, network ana-
lysis was also performed on proteins differentially regu-
lated in old GBM versus old peritumoural-control.
Network analysis is a powerful tool for identifying poten-
tial interactions between altered proteins (hypothesis gen-
eration) which can be subsequently explored in functional
analyses.
Results
The median survival in the young GBM cohort was
[39 months (3 of the 7 patients are still alive) and this was
significantly greater than the median survival of 9 months
in the older reference group (p \ 0.02). Performance status
(see Supplementary Table 1) was not significantly different
between the young (mean age 36 years) and old (mean age
67 years) GBM cohorts.
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Table 1 Proteins altered in young GBM
Spot ID Protein ID Protein accession number Young GBM Old GBM Main protein function
Fold change p value Fold change p value
746 CKMT1A P12532 0.32 1.76E-08 0.53 3.95E-05 ATP homeostasis
749 GNB1* P62873 0.59 2.05E-07 0.63 2.29E-05 GPCR beta subunit
757 DPYSL2 Q16555 0.4 3.94E-07 – – Cytoskeletal
798 INA Q16352 0.36 4.21E-07 0.59 0.00240 Cytoskeletal
271 ALDOA P04075 0.71 5.48E-07 1.3 0.00034 Glycolysis
310 CRYM Q14894 0.37 7.79E-07 0.55 9.96E-05 –
768 STMN1 P16949 0.38 8.37E-07 0.59 0.00015 Cytoskeletal
161 GDI2 P50395 0.34 9.28E-07 – – –
119 OXCT1 P55809 0.37 9.71E-07 – – Lipid metabolism
67 DPYSL2 Q16555 0.45 1.11E-06 0.63 0.00246 Cytoskeletal
760 VDAC2 P45880 0.53 1.28E-06 0.53 1.40E-06 Ion transport
763 GOT1 P17174 0.53 2.09E-06 0.53 1.86E-05 Amino acid metabolism
736 GNB1* P62873 0.43 2.32E-06 0.47 1.05E-06 GPCR beta subunit
343 NAPB Q9H115 0.5 2.34E-06 0.55 7.05E-06 Ca2? mediated exocytosis
469 NDUFS3 O75489 2.9 2.83E-06 2.5 3.00E-06 Electron transport
492 C1orf128 Q9GZP4 0.36 3.55E-06 0.5 2.36E-05 unknown
120 OXCT1 P55809 0.48 3.70E-06 0.63 0.00026 Lipid metabolism
451 PNPO* B4E152 2.1 6.70E-06 – Pyridoxine biosynthesis
249 TUBB2A Q13885 0.5 7.44E-06 – Cytoskeletal
243 – – 0.59 1.25E-05 0.59 1.29E-05 –
938 MBP P02686 0.53 1.36E-05 – Myelin
809 PSAT1 Q9Y617 0.53 1.45E-05 – Amino acid biosynthesis
84 INA Q16352 0.33 1.51E-05 0.45 3.21E-05 Cytoskeletal
613 PGAM1 P18669 0.33 1.68E-05 0.55 0.00044 Glycolysis
428 PSME1 Q06323 2.3 1.76E-05 2.0 3.40E-05 Immunoproteosome
734 TUBB2A Q13885 0.42 1.79E-05 0.48 1.46E-06 Cytoskeletal
785 UCHL1 P09936 0.59 1.89E-05 0.55 9.13E-06 Stabilises free ubiquitin
544 TAGLN3 Q9U115 0.5 2.55E-05 0.5 4.52E-07 Neuronal growth
1046 TUBB2C P68371 0.45 2.59E-05 0.59 0.00113 Cytoskeletal
774 PDXP Q96GD0 0.33 2.62E-05 0.5 4.72E-05 Phosphatase activity
794 PRDX3* P30048 1.9 2.72E-05 – – Antioxidant
823 HPRT1 P00492 1.6 3.32E-05 – – Purine synthesis
379 VDAC2 P45880 0.71 3.67E-05 – – Ion transport
748 NAPG Q99747 0.45 4.70E-05 0.59 9.04E-06 Vesicle transport
459 UCHL1 P09936 0.77 4.77E-05 – – Stabilises free ubiquitin
657 UBE2 N P61088 2.2 5.20E-05 – – Ubiquitination
786 SEPT11 Q92599 0.59 6.54E-05 0.63 0.00129 Vesicle transport
828 PRDX3 P30048 0.66 7.37E-05 0.77 0.00058 Antioxidant
812 PSME2 Q9UL46 2.0 9.5E-05 2.0 0.00169 Immunoproteosome
822 HSPD1 P10809 0.63 9.5E-05 0.63 0.00173 Chaperone
1062 HSPB1 P04792 0.5 0.000106 0.71 0.00219 Chaperone
69 DPYSL2 Q16555 0.66 0.000118 – – Cytoskeletal
285 ACOT7 O00154 0.5 0.000124 0.53 2.84E-05 Acetyl-CoA binding
605 MBP* P02686 0.53 0.000131 – – Myelin
116 PHGDH O43175 0.55 0.000132 0.53 0.00187 Serine biosynthesis
467 GFAP P14136 2.4 0.000148 – – Cytoskeletal
483 DCXR* Q7Z4W1 2.7 0.000186 – – Glucose metabolism
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Table 1 continued
Spot ID Protein ID Protein accession number Young GBM Old GBM Main protein function
Fold change p value Fold change p value
868 UCHL1 P09936 0.66 0.000229 – – Stabilises free ubiquitin
276 IDH3A P50213 0.48 0.000239 0.59 3.65E-06 TCA cycle
916 CKB P12277 0.66 0.000245 0.66 1.49E-05 ATP homeostasis
487 TPI1 D3DUS9 2.1 0.000251 – – Glycolysis
556 PEBP1 P30086 2.7 0.000255 – – Intracellular signaling
718 DCD A5JHP3 0.37 0.000259 0.43 3.06E-06 Phosphatase activity
66 DPYSL2 Q16555 0.63 0.000316 – – Cytoskeletal
92 CCT6A P40227 2.2 0.000391 2.0 0.000454 Protein folding
91 HIST1H4A* P62805 1.6 0.000479 – – Chromatin binding
498 GRB2 P62993 0.63 0.000499 – – Signal transduction
273 hCG_2002* Q59GE1 0.71 0.000548 0.66 6.60E-05 Neuron growth
579 DCD A5JHP3 2.4 0.000596 – – Phosphatase activity
62 DPYSL2 Q16555 1.7 0.000689 – – Cytoskeletal
756 ATP6V1E1 P36543 0.71 0.000709 0.63 2.82E-05 Energy metabolism
437 CLIC* Q9Y696 2.4 0.000737 2.5 0.000155 Ion transport
288 TUBB2A Q13885 0.66 0.000745 – – Cytoskeletal
731 TF* P02787 1.5 0.000749 – – Iron transfer
843 PDIA3 P30101 1.4 0.000751 1.3 0.00263 Protein folding
409 HSPA5 P11012 2 0.000810 1.8 0.00035 Chaperone
488 APOA1* P02647 0.55 0.000811 0.53 0.00026 Lipid metabolism
270 ALDOA P04075 0.71 0.000941 0.66 0.00124 Glycolysis
771 GFAP* P14136 1.8 0.000971 1.7 0.000953 Cytoskeletal
740 HSPB1 P04792 0.66 0.00101 0.71 0.00193 Chaperone
898 GLUD1* P00367 1.4 0.00107 – – Glutamate turnover
966 ATP6V1B2 P21281 0.59 0.00112 – – Energy metabolism
263 OvBr SEPT Q9UHD8 0.66 0.00114 – – Cytoskeletal
789 hCG_2002 Q59GE1 0.59 0.00115 – – Neuronal growth
801 SEPT11 Q9NVA2 0.63 0.00124 0.66 0.00104 Vesicle transport
154 SEPT11 Q9NVA2 0.71 0.00133 0.63 0.00161 Vesicle transport
28 GPD2 P43304 1.9 0.00149 – – Lipid metabolism
207 ACTR1B P42025 0.63 0.00169 – – Cytoskeletal
25 HSPA8 P11142 0.63 0.00187 – – Chaperone
1012 SRI P30626 1.8 0.00191 – – Calcium homeostasis
516 GSTP1 P09211 1.3 0.00192 1.2 0.000867 Free radical clearance
342 DKFZp686 P07355 1.4 0.00193 1.9 0.00220 unknown
572 TAGLN3 Q9U115 2.8 0.00200 – – Neuronal growth
81 CAT P04040 1.4 0.00218 – – Nucleotide binding
434 GSTO1 P78417 1.5 0.00234 – – Glutathione metabolism
444 ACOT7 O00154 1.6 0.00239 – – Acetyl-CoA binding
838 PGAM1 P18669 1.6 0.00249 – – Glycolysis
876 ALAD* P13716 1.6 0.00251 – – Haeme production
324 TUBB2B Q9BVA1 0.77 0.00263 – – Cytoskeletal
403 GNB1 P62873 0.63 0.00269 – – GPCR subunit
829 SNCG A9XXE1 – – 0.38 7.58E-09 unknown
945 HIST1H4A P62805 – – 1.6 1.79E-05 Chromatin binding
277 ALDOA P04075 – – 0.71 3.98E-05 Glycolysis
401 CLIC1 O00299 – – 0.55 0.000135 Ion transport
82 J Neurooncol (2014) 119:79–89
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Young GBM: proteins differentially expressed in young
GBM compared to age matched controls
A total of 405 protein spots were matched across every
2Dgel (young GBM and young peritumoural-control gels)
and analysed. Logarithmic association of the 405 protein
expression levels (mean normalised volumes) highlights
multiple protein alterations in young GBM (Fig. 1a, Sup-
plementary Fig. 2). 90 protein spots were altered in young
GBM (versus young peritumoural-control; p B 0.01) and
the identity of these 90 statistically significant altered spots
was established by LCMS.
Sixty eight unique proteins were significantly altered in
young GBM (Table 1, Supplementary Table 3). 15 of these
proteins were identified multiple times in 2–5 spots
(ATP6V1B2, OXCT1, ALDOA, GFAP, DCD, DPYSL2,
TUBB2A, INA, MBP, ACOT7, VDAC2, UCHL1,
PGAM1, PRDX3 and GNB1). Identification of the same
protein in several spots is a feature of 2DGE proteomic
studies and explains the difference between the number of
altered protein spots and number of unique proteins
identified. From the 68 altered proteins identified, 29 pro-
teins were up-regulated and 39 proteins were down-regu-
lated. A major fraction of the proteins altered in young
GBM (25 %; 16 out of the 68 proteins) are putatively
localised to mitochondria (OXCT1, PEBP1, DPYSL2,
CKMT1A, ACOT7, CKB, IDH3A, SNAP, VDAC2,
PRDX3, HSPD1, CAT, ATP6V1E1, GLUD1, CLIC4 and
NDUFS3). 12 of the 68 proteins altered in young GBM
have previously been described altered in proteomic stud-
ies of glioma (APOA1, GFAP, HSPA5, PDIA3, TUBB2A,
GLUD1, GSTP1, PGAM1, UCHL1, HSPB1, HSPD1 and
SRI) [5]. Notably, over 50 proteins have been described
altered in GBM for the first time.
Ten proteins (DPYSL2, SRI, OXCT1, UCHL1, CAT,
SEPT11, IDH3A, PDIA3, ATP6V1B2, PRDX3), altered in
young GBM were examined using western blotting. Wes-
tern blotting of young GBM versus young peritumoural-
control tissue, demonstrated that 7 out of the 10 proteins
tested were significantly altered (p B 0.01) and that 10 out
of the 10 proteins showed the same direction of response as
the proteomic analysis (Fig. 2, Supplementary Fig. 3).
Table 1 continued
Spot ID Protein ID Protein accession number Young GBM Old GBM Main protein function
Fold change p value Fold change p value
1073 UQCRFSL P0C7P4 – – 0.66 0.000261 unknown
772 PSMB7 Q99436 – – 1.5 0.000261 20 s proteosome
564 PEBP1 P30086 – – 0.71 0.000298 Intracellular signaling
840 MAP2K1 Q02750 – – 0.71 0.000313 Intracellular signaling
317 LASP1 Q14847 – – 1.8 0.000322 Cytoskeletal
466 – – – – 1.7 0.000437 –
217 GLUL P15104 – – 0.55 0.000471 Glutamine synthesis
223 SUCLA2 Q9P2R7 – – 0.55 0.000493 TCA cycle
299 DDAH1 O94760 – – 0.71 0.000548 NO regulation
227 CKB P12277 – – 0.77 0.000996 ATP homeostasis
601 SOD1 P00441 – – 0.63 0.00102 Antioxidant
419 PAFAH1B2 P68402 – – 1.5 0.00111
1028 – – – – 1.5 0.00129 –
443 – – – – 1.9 0.00185 –
530 PRDX1 Q06830 – – 1.5 0.00214 Antioxidant
653 PRDX5 P30044 – – 0.77 0.00237 Antioxidant
845 GLUL P15104 – – 0.63 0.00238 Glutamine synthesis
375 – – – – 0.71 0.00257 –
Proteins significantly altered in young GBM relative to young peritumoural controls are listed (ordered by p value). Only significant protein
changes are listed (p values shown are prior to Bonferroni correction with a factor 3). Spot ID provides a unique 2DGE spot identifier and is
important because several proteins were identified in multiple spots, for example OXCT1 in spot 119 and spot 120. Proteins marked with an
asterisk indicate a spot where a second protein (or occasionally more) is present at a level close to that of the listed protein. Blank protein IDs (for
example spot 243) represent where protein identity could not be established. The protein accession numbers (Uniprot), magnitude of protein
response and p values (ranked according to changes in young GBM) are listed for each altered protein. For comparison, proteins significantly
altered in old GBM, relative to old controls are listed. Blank values, for example Spot757 (DPYSL2) in old GBM, indicate that the significant
change in this protein in young GBM did not achieve statistical significance in the old cohort (see Supplementary Table 3 for more details and
information on fold change and probability levels for proteins that failed to reach the pre-determined significance level (i.e. p \ 0.003)
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IPA network analysis was performed on the proteomic
dataset referred to as young GBM and included 68 proteins.
The young GBM dataset generated multiple functional
protein networks (Table 2) including 4 high scoring net-
works containing 23, 15, 12 and 11 dataset proteins
respectively (Table 2).
The top network generated by IPA (Fig. 3) included
multiple structural proteins downregulated in young GBM,
for example Strathmin (STMN1) and dihydropyrimidinase-
related protein 2 (DPYSL2). The network also contained
GFAP, upregulated in young GBM, which has long been
considered a fundamental and diagnostic feature of glioma
[23]. The network included heat shock proteins (HSPD1,
HSPA8, HSPB1), and a group of downregulated proteins
involved in ATP homeostasis and energy metabolism
(ALDOA, ATP6V1E1, CKB, CKMT1A), consistent with
existing evidence but also identifying for the first time
specific protein networks that may be involved in the
dysregulation of energy metabolism in malignant glioma
[24]. Lastly a cluster of upregulated proteins, integral to the
immunoproteosome (PSME1, PSME2, 20 s/26 s proteo-
some, PSMB7), was highlighted in the top network. Net-
work 2 was characterised by a cluster of Septin proteins
(GTPase proteins that have been shown to play a role in
gliomagenesis [25], and the insertion of a hub protein,
TRAF6, a signal transducer in NFkappaB signalling. Net-
work 3 was characterised by the insertion of a hub protein
HNF4alpha, a transcription factor recently shown to play a
role in other neoplasias [26] and Network 4 was charac-
terised by numerous mitochondrial-localised proteins
(CAT, IDH3A, NDUFS3 and other complex 1 proteins,
OXCT1 and PRDX3).
Old GBM: proteins differentially expressed in Old
GBM compared to age matched control tissue
To allow the extensive protein alterations in young GBM to
be compared with those in old GBM, a proteomic evalu-
ation was conducted contemporaneously in old GBM
(patients[60 years) using the same technology. A total of
405 protein spots were matched across every 2D gel (old
GBM and old peritumoural-control gels) and analysed.
Logarithmic association of the 405 protein expression
levels (mean normalised volumes) was broadly similar to
that seen in young GBM (Supplementary Fig. 2). 70 pro-
tein spots were altered in old GBM versus old peritumo-
ural-control (p B 0.01).
55 unique proteins were altered significantly in old
GBM (listed in Table 1 and Supplementary Table 3 in
full). 8 of these proteins were identified multiple times in
2-4 spots (GNB1, INA, ALDOA, SEPT11, HSPB1,
CKB, CLIC and GLUL). From the 55 altered proteins
identified, 16 proteins were up-regulated and 39 proteins
were down-regulated. 19 of the 55 proteins have been
reported to be putatively localised to mitochondria
Fig. 1 a Overview of proteomic analysis of young GBM. Over 400
spots were identified by 2D gel electrophoresis. The normalised
volume represents the relative amount of protein in the spot. Each
point in the graph represents the relative amount of protein in the 400
spots analysed. Table 1 lists the proteins which are significantly
altered in young GBM. In contrast this graph emphasises that the
levels of the majority (more than 75 %) of proteins are unaltered in
young GBM. Because of the dynamic range (300 fold difference from
the most abundant to the least abundant protein), data are presented as
logs. There is a good correlation between young GBM and young
peritumoural control (r2 = 0.85), with 22 % of the spots significantly
altered (see Supplementary Table 1). b Overview of proteomic
response in young GBM compared to old GBM. Over 400 spots were
identified by 2D gel electrophoresis. The normalised volume repre-
sents the relative amount of protein in the spot. Each point in the
graph represents the relative amount of protein in the 400 spots
analysed. There is an excellent correlation between young GBM and
old GBM (r2 = 0.95) with only 1 % of the spots significantly altered
(5 out of 405; see text for details)
84 J Neurooncol (2014) 119:79–89
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(OXCT1, ATP6V1E1, NAPG, NDUFS3, ACOT7, CKB,
CKMT1A, DPYSL2, GLUL, HSPD1, IDH3A, PRDX1,
PRDX3, PRDX5, PEBP1, SUCLA2, SOD1, UQCRFSL1
and VDAC2; 13 of these 19 proteins were also altered in
young GBM). 9 of the 55 proteins have previously been
described altered in proteomic studies of glioma
(APOA1, GFAP, HSPA5, PDIA3, GSTP1, UCHL1,
HSPB1, HSPD1 and PRDX1; 8 of these 9 proteins were
also altered in young GBM). Over 40 proteins have been
described altered in GBM for the first time (24 of which
were also altered in young GBM).
As in young GBM, protein alterations were confirmed
by Western blot analysis: 8 out of 10 proteins tested were
significantly altered (p B 0.01) and 10 out of the 10 pro-
teins showed the same direction of response as the pro-
teomic analysis (Supplementary Fig. 4).
The highest scoring networks for old GBM highlighted
considerable commonality to the proteomic response in
young GBM (Table 2).
Proteomic response in young GBM: a comparison
with the proteomic response in old GBM
Five protein spots were differentially altered between
young and old GBM (p B 0.01). Only three unique sta-
tistically altered proteins were identified (PEBP1,
NDUFA10 and PGK1). The proteins in two spots were not
identified. This number of altered proteins lies beneath the
multiple testing threshold of potential false positive results
in the study. There was an excellent correlation (r2 = 0.95)
between the level of 405 proteins analysed in GBM from
younger patients and their level in GBM from older
patients (Fig. 1b). This correlation was similar to that seen
in peritumoural-control samples from the two age groups
(Supplementary Fig. 2). There were good correlations
(r2 = 0.85 and 0.90) between the level of 405 proteins in
young GBM relative to young peritumoural-controls
(Fig. 1a) and old GBM relative to old peritumoural-control
(Supplementary Fig. 2) respectively. 48 unique proteins
Fig. 2 Proteomic alterations in young GBM: confirmation with
western analysis. Western blotting replicates the alterations in defined
proteins in GBM in a subset (determined by tissue availability) from
the same subjects as used in the proteomic 2D gel electrophoresis.
a 2D gel electrophoresis identified a consistent significant
(p = 1.8E-06) reduction in DPYSL2 in young GBM. b Western
blot analysis identified a similar consistent reduction in DPYSL2 in
young GBM. c 2D gel electrophoresis identified a significant increase
(p = 0.0057) in Sorcin (though with inter-subject variability) in
young GBM. d Western blot analysis identified a similar increase in
Sorcin in young GBM, again with inter-subject variability. There was
also good correspondence between 2D gel electrophoresis and
western blot analysis in young GBM for all 10 proteins examined
with both techniques (see Supplementary Fig. 3)
J Neurooncol (2014) 119:79–89 85
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altered in GBM were common in young and old cohorts.
The direction and fold change of all 48 proteins was con-
sistent in both young and old GBM. From the top 25 altered
protein spots identified in Young GBM (ranked by
p value), 17 were demonstrated altered in old GBM
(p B 0.01).
Discussion
The present study provides a powerful example of how
proteomics can reliably test a hypothesis (i.e. is the most
important prognostic variable in GBM, age, associated with
a distinct response) and demonstrates that proteomics can
play an important role in understanding GBM pathophysi-
ology. Definition of the proteomic response in samples from
patients with a homogeneous and clinically defined age
range (18–45 years) addresses one of the design weaknesses
in proteomic studies of GBM to date [5].
Young (\45 years of age) and old ([60 years of age)
GBM cohorts with a mean age difference of 31 years and a
significantly better median survival despite optimal therapy
in the younger cohort were recruited. Multiple protein
alterations were detected in young and old GBM versus age
matched control tissue, and included a mixture of previously
well-characterised protein alterations in GBM (for example,
GFAP and UCHL1), and the identification of many ‘highly
expected’ heat shock proteins (HSPD1, HSPB1, HSPA5,
HSPA8) and cytoskeletal proteins (TUBB2A, TUBB2C),
which confirm the robustness of our proteomic data.
One cluster of upregulated proteins (Fig. 3) in both
young and old GBM comprised PSME1, PSME2, 20 s/26 s
proteosome and PSMB7. These interacting proteins are
central to the immunoproteosome (i-proteosome). All
proteasomes contain a 20 s subunit flanked by either 19 s
subunits or 11 s subunits. In the standard proteasome two
19 s subunits enclose a 20 s subunit of 2a rings sand-
wiching 2b rings with proteolytic subunits (b1, b2, b5).
In the i-proteasome these catalytic subunits are substituted
by LMP2, MECL, LMP7 and the 20 s is flanked by two
11 s/PA28 subunits. The 11 s contains 3a & 3b alternating
subunits regulated by PSME1 and PSME2 respectively
[27], two of the proteins upregulated in our young and old
GBM analyses. Inhibition of the 20 s/26 s proteasome by
Fig. 3 Protein-protein interactions in young GBM. Visual represen-
tation of putative protein–protein interactions in Network 1 (the
highest scoring network; Table 2) generated by IPA in young GBM.
Each node (shape) represents a protein and its association with other
proteins, is represented by a line. Nodes have different shapes that
represent different molecule types, for example, transcription factors,
enzymes, kinases and phosphatases (refer to Ingenuity Systems
Software for detailed node information). Proteins or ‘nodes’ with a
coloured background were regulated in the study (green = downreg-
ulated; red = upregulated) whilst other interacting proteins with no
background are proteins not detected in this study that have been
inserted by IPA to produce a highly connected network. The solid
lines represent direct interactions or associations between proteins
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drugs, such as carfilzomib leads to a build up of poly-
ubiquinated proteins causing cell cycle arrest, apoptosis
and inhibition of tumour growth [28].
i-proteasome function is to provide peptides for MHC-
class1-antigen presentation. Interferon increases i-protea-
some numbers during inflammation and oxidative damage
[29]. 26 s proteasomes are ineffective at degrading oxidised
proteins, but i-proteasomes can efficiently process these
damaged proteins [27]. Increased PSME1 and PSME2 as a
result of interferon, would prevent protein build up and
apoptosis. Conversely loss of i-proteasome function, through
inhibition of 11 s subunit formation or joining of the 11 s
subunit to the 20 s, would have the two fold effect of dam-
aged protein aggregation, leading to apoptosis; and the
removal of ‘self’ peptides from the cell surface, alerting the
immune system to the malignant tumour cells. Elucidating
the mechanisms of GBM immune resistance and causes of
immunosuppression is currently an area of intense research
and therapeutic effort in GBM [30, 31].
The proteomic analyses of young and old GBM also
highlighted multiple proteins (PRDX3, UCHL1, PEBP1,
DPYSL2, UBE2 N, GSTO) involved in nuclear factor
kappaB (NFkB) regulation. NFkB is a transcription factor
capable of mediating many cellular responses and modu-
lates oncogenesis, tumour progression and chemotherapy
resistance [32–35]. In the cytoplasm, NFkB is a small
protein complex containing two subunits that bind inhibi-
tory kappa B (IkB). IkB binding prevents NFkB translo-
cation to the nucleus. Activation of NFkB, with subsequent
translocation to the nucleus can occur through the canon-
ical (utilising IkB kinase, IKK), the non-canonical or the
alternative pathway. In the nucleus NFkB regulates tran-
scription of proteins that down-regulate apoptosis, increase
cell invasiveness, increase angiogenesis and increase vas-
cular permeability, thereby promoting tumourgenesis [32,
36]. Proteins that regulate NFkB function were altered in
GBM. GSTO1 (upregulated in the young GBM analysis)
increases IL1b levels which activates IKK. GSTO1 also
increases Akt phosphorylation in cells exposed to the pro-
apoptotic drug cisplantin. Phosphorylated Akt inhibits
apoptosis via NFkB [37]. UBE2 N (also upregulated in the
young GBM analysis) is also vital for the activation of
IKK via TRAF6 [38]. TRAF6, a core signal transducer in
the NFkB pathway was highlighted as a hub protein in
IPA Network 2 of both young and old GBM IPA analyses.
PRDX3 (downregulated in young and old GBM analyses)
also increases IKK activation [39], and knock-down
studies of UCHL1 (also downregulated in young and old
GBM analyses), show an increase in NFkB function via
IKK activation [40]. PEBP1 (upregulated in young GBM
and downregulated in old GBM) antagonises NFkB
function by interfering with the TNFa pathway [41],
resulting in an increase in NFkB function. NFkB’s role in
gliomagenesis is summarised in Supplementary Fig. 5.
NFkB inhibitors have shown promise in inducing cell
death in GBM [42].
Alignment of protein alterations identified in young and
old GBM versus age-matched peritumoural-controls showed
considerable commonality in the proteomic response of
GBM in different aged patients (and also demonstrated the
rigour of our two distinct proteomic analyses of GBM). Our
study does not provide a clear explanation as to why young
and old patients with GBM have differential prognoses. One
of the few proteins putatively altered in expression level
between young and old GBM, is Phosphatidyl ethanolamine
binding protein 1 (PEBP1; also known as Raf1-kinase
inhibitor protein, RKIP). PEBP1 was found significantly
upregulated in our young GBM proteomic analysis, signifi-
cantly downregulated in our old GBM analysis, and signifi-
cantly downregulated in old GBM compared to young GBM.
PEBP1 inhibits the RAF/MEK/ERK pro-oncogenic pathway
and also inhibits NFkB (also pro-oncogenic) by antagonising
the activity of IKK either directly or via Tumour Necrosis
Factor alpha (TNFalpha) [41]. The difference in PEBP1
expression levels between young and old GBM could con-
tribute to their different prognosis.
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